BRPI0507190A - combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores - Google Patents

combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores

Info

Publication number
BRPI0507190A
BRPI0507190A BRPI0507190-9A BRPI0507190A BRPI0507190A BR PI0507190 A BRPI0507190 A BR PI0507190A BR PI0507190 A BRPI0507190 A BR PI0507190A BR PI0507190 A BRPI0507190 A BR PI0507190A
Authority
BR
Brazil
Prior art keywords
disorder
syndrome
pharmaceutically acceptable
gamma
disorders
Prior art date
Application number
BRPI0507190-9A
Other languages
English (en)
Inventor
Harry Ralph Howard Jr
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0507190A publication Critical patent/BRPI0507190A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINAçãO DE MODULADORES DO áCIDO GAMA-AMINOBUTìRICO E ANTAGONISTA DE 5-HT~ 1b~ RECEPTORES. A presente invenção refere-se a uma composição farmacêutica para tratar um distúrbio ou condição selecionados entre o grupo consistindo em hipertensão, depressão, distúrbio de ansiedade generalizado, fobias, distúrbio de estresse pós-traumático, distúrbio de personalidade de evitação, disfunção sexual, distúrbios alimentares, obesidade, dependências químicas, cefaléia em cacho, enxaqueca, dor mal de alzheimer,transtorno obessivo compulsivo, distúrbio de pânico,distúrbio da memória, doenças de parkinson, distúrbiosendócrinos, ataxia cerebelar, distúrbios do trato gastrointestinal, sintomas negativos de esquizofrenia, síndrome pré-menstrual, síndrome de fibromialgia, incontinência do estresse, sídrome de tourette, tricotilomnia, cleptomania, impotência masculina, câncer, hemicrania paroxísmica crónica e cefaléia em um mamífero, preferencialmente um ser humano, compreendendo (i) um modulador do ácido<sym>-aminobutírico ou um sal farmaceuticamente aceitável do mesmo, (ii) um antagonista de receptores 5-HT~1b~ ou um sal farmaceuticamente aceitável do mesmo, em que o antagonista de receptores 5-HT~1b~ é selecionado entre o grupo consistindo em (A) um composto da fórmula l conforme descrito na especificação e (B) um composto da fórmula ll conforme descrito na especificação, e opcionalmente (iii) um veículo farmaceuticamente aceitável.
BRPI0507190-9A 2004-01-29 2005-01-17 combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores BRPI0507190A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54051704P 2004-01-29 2004-01-29
PCT/IB2005/000096 WO2005082372A1 (en) 2004-01-29 2005-01-17 COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
BRPI0507190A true BRPI0507190A (pt) 2007-06-26

Family

ID=34910693

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507190-9A BRPI0507190A (pt) 2004-01-29 2005-01-17 combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores

Country Status (6)

Country Link
US (1) US20050182049A1 (pt)
EP (1) EP1737466A1 (pt)
JP (1) JP2007537151A (pt)
BR (1) BRPI0507190A (pt)
CA (1) CA2553291A1 (pt)
WO (1) WO2005082372A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO2005113526A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
WO2007146073A2 (en) * 2006-06-09 2007-12-21 Wyeth Method for enhancing cognitive function
EP2058008B1 (en) * 2006-08-11 2013-08-21 National University Corporation Nagoya University Anti-obesity agent and use thereof
US20160151316A1 (en) * 2012-01-27 2016-06-02 Catalyst Pharmaceutical Partners Method of treating tourette's disorder with gaba-aminotransferase inactivators
WO2013137479A1 (en) * 2012-03-12 2013-09-19 Otsuka Pharmaceutical Co., Ltd. Decahydroquinoxaline derivatives and analogs thereof
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH449645A (de) * 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) * 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US3960927A (en) * 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
DK153787C (da) * 1979-06-01 1989-01-16 Wellcome Found Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
EA001485B1 (ru) * 1996-03-29 2001-04-23 Пфайзер Инк. Производные бензил(иден)-лактамов, их получение и применение в качестве селективных (ант)агонистов рецепторов 5-htи/или 5-ht
EP0810220B1 (en) * 1996-05-28 2001-12-12 Pfizer Inc. Arylacrylamide derivatives as 5HT1 agonists or antagonists
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
ATE273970T1 (de) * 1998-04-16 2004-09-15 Pfizer Prod Inc N-acyl und n-aroyl aralkylamide
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
ATE294577T1 (de) * 1999-02-24 2005-05-15 Univ Cincinnati Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
DE60013751T2 (de) * 1999-12-29 2005-09-29 Pfizer Products Inc., Groton Optisch aktive 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone als selektive 5-HT1D Rezeptor Antagonisten
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety

Also Published As

Publication number Publication date
CA2553291A1 (en) 2005-09-09
EP1737466A1 (en) 2007-01-03
WO2005082372A1 (en) 2005-09-09
US20050182049A1 (en) 2005-08-18
JP2007537151A (ja) 2007-12-20

Similar Documents

Publication Publication Date Title
BRPI0507190A (pt) combinação de moduladores do ácido gama-aminobutìrico e antagonistas de 5-ht1b receptores
BRPI0510942A (pt) combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
BRPI0513433A (pt) derivados de hidantoìna para o tratamento de distúrbios inflamatórios
BRPI0506721A (pt) composto ou um sal de adição de ácido do mesmo
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
CR10866A (es) Derivados de aril sulfamida y metodos para su uso
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
EP2426115A3 (en) Alkynyl derivatives as modulators of metabotropic glutamate receptors
MA30337B1 (fr) Anticorps
WO2008073956A3 (en) Cyclic sulfonamide derivatives and methods of their use
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
EA200601802A1 (ru) Производные морфолина
WO2007081542A3 (en) Tetralone-based monoamine reuptake inhibitors
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
CR8639A (es) Derivados propan-2-ol fenil heterociclicos y compuestos relacionados como moduladores de la norepirefrina (ne) y la actividad de setotonina (5-ht) y la recaptacion de monoamina para el tratamiento de sintomas vasomotores (vms)
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
WO2006065600A3 (en) N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
BRPI0506436A (pt) combinação de antagonistas de crf e antagonistas de receptor de 5-ht1b
BRPI0816571A2 (pt) &#34;composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6&#34;
BRPI0509513A (pt) derivados de fenilaminopropanol heterocìclicos como moduladores da captação de monoamina para o tratamento de sintomas vasomotores (vms)
ECSP088300A (es) Derivados de benzotiadiazolilfenilalquilamina para uso en el tratamiento de condiciones mejoradas por la retoma de monoamina
BRPI0415410A (pt) derivados de arilalquil-e cicloalquilalquil-piperazina e métodos de seu uso
AR061147A1 (es) Compuestos derivados de piperazina, un proceso para su preparacion y una composicion farmaceutica
BRPI0415380A (pt) derivados aril ciclo alcanol substituìdos e processos de seus usos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A E 6A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.